All News

key solution goal plan problem solve

Diagnostic tools in autoinflammatory syndromes

d Olga Petryna, MD

With broader awareness about the disease state, early diagnosis and treatment in autoinflammatory syndromes, and its life threatening complication Macrophage Activation Syndrome, remains a huge unmet need.

Read Article
heart.jpg (keep)

FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat

d Meral K. El Ramahi, MD, FACP, FACR

Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc

Read Article
covid19.logo_.jpg

Answering questions on how COVID-19 affects rheumatic patients

d Jeffrey Sparks

As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.

Read Article
physical therapy

Systemic Sclerosis and Physical Therapy

d Sheila Reyes, MD

Systemic sclerosis (SSc) is a chronic fibrosing disease currently with no available cure.

Read Article
Hypophosphatasia - CPPD/chondrocal, enthesop'y, DISH, exostoses - DDx of Low ALP: milk-alkali, Vit D intoxic'n, Wilson dz, via C def, celiac dz, adyn renal osteodystrophy, Cushing dz, hypothyroid, major sx, MM Rx - asfotase alpha- bone targeted replac't Rx #ACR20 #ACRambassador https://t.co/FJ1355MdKG
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
#ACR20 Abstracts on #ILD Rituximab in ILD (all observational) #1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m #1051 ➡️ 50 with IPAF: >70% stable or improved at 12m #1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX #ACRambassador https://t.co/klfVwIH5b6
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Over 20,000 tweets and 65 Million+ Impressions Check out the details at https://t.co/Z6X1EeOsnr https://t.co/OtqWZCiu6h

Links:

Steven Echard, CAE StevenEchard ( View Tweet)
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj

Links:

The Lancet TheLancet ( View Tweet)
Congrats to Dr @DrDavidKarp on your installation as president of @ACRheum and thanks Dr Ellen Gravallese outgoing president on your outstanding leadership in this year! #ACR20 https://t.co/q0r5URWrEr
Angus Worthing MD AngusWorthing ( View Tweet)
There are a number of important mimics of IgG4-RD that should be considered 🔵ANCA-associated vasculitis 🔵Multicentric Castleman’s disease 🔵Rosai-Dorfman disease 🔵Inflammatory myofibroblastic tumour 🔵Cutaneous plasmacytosis 🔵Erdheim-Chester disease 🔵Malignancy #ACR20

Chris Wincup chriswincup ( View Tweet)

Check out our article titled Undifferentiated Autoinflammatory Syndrome Called VEXAS by @RheumNow. We recap Saturday's session on autoinflammatory syndromes featuring Dr. Dan Kastner. #ACR20 https://t.co/afNK3UuZef https://t.co/qGvC2ylmjL

Links:

Dr. John Cush RheumNow ( View Tweet)
Want the highlights of #ACR20 Day 4? Check out our podcast through the link below or through Apple and Android podcasts. Just look up "Rheum Now". https://t.co/EHcrkIxAez https://t.co/K2pzQPcgdB

Links:

Dr. John Cush RheumNow ( View Tweet)
The folly of dietary restriction in contemporary gout? by @RichardPAConway Dr. Conway discusses the abstracts presented at #ACR20 https://t.co/bJBKXKdftO https://t.co/Y5MXcNJQmS

Links:

Dr. John Cush RheumNow ( View Tweet)
Telemedicine Studies: A Trainee’s Perspective by Mrinalini Dey ( @DrMiniDey ) COVID-19 has shifted face to face to consultations--an important change in rheumatology practice. #ACR20 https://t.co/T2iUwE7XUo https://t.co/AyQ6X2fOJA

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jonathan Kay leads an international panel of rheumatologists to elicit their opinions on key abstracts at #ACR20. Panelists: @drdavidliew, @ejdein1, @MeralElRamahiMD, @RichardPAConway, @RHEUMarampa, and @jeffsparks https://t.co/btZKgwvoSn https://t.co/Okdvx9HuNc

Links:

Dr. John Cush RheumNow ( View Tweet)
TAK & GCA differ in vessel involvement when it comes to the 👁👁 > TAK- large vessel lesions > GCA- small vessel vasculitis @RheumNow #ACR20 https://t.co/sa4VEvCKOt
sheila RHEUMarampa ( View Tweet)
I would usually be on a Transatlantic flight at this point post-ACR. Going #virtual is great as I never left. What did you miss most about a face to face conference? @RheumNow #ACR20

Dr. Antoni Chan synovialjoints ( View Tweet)

Dr. Cush and Dr. Kavanaugh recaps the #ACR20 meeting during #RheumatologyRoundUp highlighting important studies that were presented during the mtg and how they might impact practices. Log into https://t.co/3hCmtuN7kj to view this and all our videos/news stories. @RheumNow https://t.co/HgiA1QrdIX

Links:

k dao KDAO2011 ( View Tweet)
IgG4-RD tx: GCs are mainstay tx starting at 30-40mg/d tapered gradually but 30% of pts will have recurrences Potential therapeutic targets to ⬇GC toxicity ✏B cell/plasmablasts (promising) ✏T cells (anecdotal) @RheumNow #ACR20 https://t.co/X2NI3vFUgl
sheila RHEUMarampa ( View Tweet)

”Somatic mutation (in UBA1) may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Kastner. Have you seen VEXAS in your clinic? #ACR20

@RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

×